VTRSViatris
Price
+84%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality shaky, hard red flags, undemanding price, growth steady, the market undecided.
Viatris is a global healthcare company whose breadth and scale we believe make it uniquely positioned to address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, Viatris supplies high-quality medicines to approximately 1 billion patients around the world each year. The Company has a global footprint, an extensive portfolio of medicines that is well-diversified across therapeutic areas, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Viatris (VTRS) reported revenue of $3.76B in Q2 2026 (quarter ended Jun 30, 2026), up 4.9% from the same quarter a year earlier. That came with a gross margin of 39% and net loss of $119M. For the full year FY2025, revenue was $14.3B (−3.0% year on year) and net income −$3.51B. Its largest product in Q2 2026 was Brands at $1.12B, 30% of the disclosed total, just ahead of Generics at 29%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 8, 2026Agreement and Plan of Merger On October 8, 2026, Viatris Inc., a Delaware corporation (“Viatris”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Pacira BioSciences, Inc., a Delaware corporation (“Pacira”), and Peach Purchaser Sub Inc., a Delaware corporation and a wholly owned subsidiary …Material agreement entered · Form 8-K
- Aug 6, 2026As previously announced, Viatris will host a conference call and live webcast today at 8:30 a.m. ET to review the Company's financial results for the period ended June 30, 2026.Earnings release · Form 8-K
- Jul 1, 2026On July 1, 2026 (the “Closing Date”), Viatris Inc. (“Viatris”) entered into an amended and restated term loan credit agreement (the “Amended and Restated Term Loan Credit Agreement”), among Viatris, the guarantors from time to time party thereto, the lenders from time to time party thereto and Mizuho Bank, Ltd., as …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $3.75BThe company’s own SEC segment disclosure.
- Brands$1.12B30%
- Generics$1.07B29%
- Lipitor$452.2M12%
- Norvasc$200.2M5%
- Epi Pen Auto Injectors$129.2M3%
- Lyrica$120.6M3%
- Other (10)$651.6M17%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
The closest names by size in the same industry